The Largest & Original (Est. 2009) Forum for Precision Medicine
A FULL TRACK DEDICATED TO THE FIGHT AGAINST COVID-19
The Largest & Original (Est. 2009) Forum for Precision Medicine
Facilitating Collaboration in the Field of Personalized Patient Care
The Largest & Original (Est. 2009) Forum for Precision Medicine
A FULL TRACK DEDICATED TO THE FIGHT AGAINST COVID-19
Facilitating Collaboration in the Field of Personalized Patient Care
See the 7-Track, 3-Day, 400-Speaker Precision Medicine Agenda
See the 7-Track, 3-Day, 400-Speaker Precision Medicine Agenda
CO-HOSTS

HONOREES

2024 -Select:

 PMWC 2024 PIONEER HONOREE, CGT TRACK
PMWC 2024 PIONEER HONOREE, CGT TRACK
PMWC 2024 PIONEER HONOREE, CGT TRACK
PMWC 2024 PIONEER HONOREE, CGT TRACK

15-MINUTE PRESENTATIONS

AUDIENCE: UP TO 200 INVESTORS, POTENTIAL CLIENTS AND PARTNERS

Apply by !

The Foremost Precision Medicine Conference

• Gathering recognized leaders, top global researchers and medical professionals, plus innovators across healthcare and biotechnology sectors

• Showcasing latest practical content that helps close the knowledge gap among different sectors

• Promoting cross-functional fertilization & collaboration to accelerate Precision Medicine

• Main Tracks and Showcases (6 Total) that provide a mix of established and upcoming perspectives

• Luminary and Pioneer Award Ceremony honoring those who transform healthcare by advancing precision medicine in the clinic

PMWC provides a valuable insight for physicians and others who may be wondering how close we are getting to realizing the arrival of personalized medicine. The conferences are helpful in understanding where and how the envelope is being pushed.


Peter Paul Yu, MD, FACP, FASCO, Immediate Past President, ASCO

See Testimonials video >

PMWC has proven, time and time again, that it attracts thought-leaders from all the relevant fields and catalyzes crucial collaboration through inspiring and practical program content. This is the Conference for entrepreneurs to meet payors, and for researchers to connect with service providers and for clinicians to hear from leading providers.


Lee Hood, PhD, MD, President, Institute for Systems Biology

See Testimonials video >

Bringing Together

DAYS

ATTENDEES (35 COUNTRIES)

EXHIBITORS

PARALLEL TRACKS

REGISTRATION

Tickets to PMWC - Est. 2009

Loading
Sale ends
Loading
Loading Waiver
$0.00
Loading Waiver
Addon Price:
$0.00
+1 Extra Ticket:
$0.00
$0.00

Ticket Rate $0.00 $0.00 $0.00 $0.00

Credit card entry
visa
Place Order & Next Step
This is an error.

Receive the latest news about the field of precision medicine and the conference from Tal Behar, PMWC’s President:

In a world grappling with a surge in chronic diseases, our approach to healthcare is evolving. The traditional model, addressing patients post-illness, is costly and lacks individualization. The existing medical care model frequently focuses on individuals only after they transition into patients, leading to elevated costs linked to treating chronic and advanced-stage illnesses. There is an emerging requirement for an interdisciplinary strategy to comprehend and manage diseases.

Next month’s PMWC January 24-26, 2024 Silicon Valley will cover structural variations (SV) which are the epicenter of change, exploring the synergy of multi-omics, AI, and precision health. The challenge in using advanced sequencing methods lies in relying on past databases for specific genetic variations. While this works well for some variations, it becomes complicated for SVs impacting certain traits, as only a fraction has been cataloged. This poses a challenge for clinicians dealing with patients exhibiting never-before-seen mutations. An exciting solution emerging is the use of multi-omics, providing additional confirmation to genomic theories. The integration of AI is poised to take this trend to the next level, promising further advancements in genetic understanding.

“Multi-omics & AI together have the potential to significantly accelerate the widespread use of ‘omics data in healthcare”, says Steve Turner, Founder of PacBio. He anticipates a transformative impact, merging multi-omics and AI for data interpretation. 2023’s rapid changes set the stage, with biology poised for a breakthrough akin to Large Language Models (LLMs).

Precision health is on the rise, driven by advancements in omics technologies and computational capabilities. Overcoming sequencing hurdles is crucial, and the exciting trend of using multi-omics for confirmation is gaining momentum. Turner states, “I am very excited as I am seeing two important trends that, both individually and together, are going to have a big impact in the next few years. I am talking about multi-omics and AI to help with the interpretation of all the data we have been – will continue – producing.”

Turner’s anticipation for PMWC 2024 Silicon Valley is fueled by the prospect of witnessing industry responses to transformative shifts, foreseeing AI tools predicting novel variant effects and ushering in a new healthcare era. He emphasizes the event’s significance, eager to learn how government and industry players are adapting to these changes. Next month’s PMWC conference promises to be thrilling, setting the stage for groundbreaking advancements and discussions.

Don’t miss the opportunity to shape the future of healthcare at PMWC January 24-26, 2024—a pivotal conference uniting experts, thought leaders and innovators to define the next era in healthcare through the intersections of multi-omics, AI, and precision health.

Key players are contributing to the program representing the various technological advancements and applications:
•    New Frontiers in Genomic Analysis & Interpretation – a panel discussion with Robert Sebra (ISMMS), Anshul Kundaje (Stanford University), Chaz Langelier (UCSF) and Orly Alter (Prism AI)
•    From Potential to Reality: Bringing Nanopore Sequencing to Clinical Practice – a panel discussion chaired by Emma Stanton (Oxford Nanopore) with Charles Chiu (UCSF)
•    Population Sequencing at Scale: Impact and Future Path of Genomic Programs – a panel discussion chaired by Stacey Gabriel (Broad Institute) with Heidi Rehm (MGH), Cindy Lawley (Olink), and John Gaziano (Million Veterans Program [MVP])
•    The Economic Perspective on Genomics – a panel discussion chaired by Bill Hyun (UCSF), Walter Kowtoniuk (Third Rock Ventures), Steve Turner (PacBio), Kandaswamy Vijayan (Zafrens) and Vishal Gulati (Recode Health Ventures)
•    NCI Showcase with Xiaofeng Xie (MicrOmics Technologies)
•    PMWC Showcase: Tara Crawford Parks (DNA Genotek), Varun Dwaraka (TruDiagnostic), John Butler (Quantumcyte, Inc), Paul Spellman (UCLA), Solomon Endlich (Base5 Genomics), Ramin Khaksar (Clear Labs)
•    Building Bridges: Precision Medicine Communities a talk by Kumar Prashant (Karkinos)

Register now before the rate goes up significantly.

Sincerely,
Tal Behar

President & Co-founder, PMWC
PMWC 2024 Silicon Valley – January 24-26, 2024

The Precision Medicine World Conference (PMWC)

We are thrilled to share some groundbreaking developments in the field of precision medicine with you. Two promising new drug candidates, Leqembi and Donanemab, have shown great potential in slowing the progression of Alzheimer’s disease, marking a significant step forward in tackling this challenging condition.

But this is just the beginning, and we must continue advancing the drug pipeline to develop the next class of drugs centered around the biology of aging to ultimately stop Alzheimer’s and related diseases in their tracks. The goal should be to address the various underlying pathologies of the disease through a precision medicine approach. Precision medicine not only benefits the patient but also the overall health systems. In addition, a precision approach to medicine is in the long run expected to help control the overall cost of health care.

A recently published PMC report showed that newly approved precision medicines in 2022 include 12 new entities and 5 newly approved gene and cell-based therapies bringing the total to 37 new molecular entities approved by the FDA’s CDER. Furthermore, 12 in vitro diagnostic testing applications that underpin precision medicine strategies were also approved or cleared for several new or expanded indications which help inform targeted treatment decisions to improve drug safety and efficacy. Some report highlights include:

• The 12 new entities represent ~34% of all newly approved therapeutic molecular entities, accounting now for at least a quarter of new drug approvals for each of the last eight years.

• The five new gene or cell-based therapies include treatments for beta thalassemia, hemophilia B, and cerebral adrenoleukodystrophy, resulting in a total of 13 FDA-approved gene or cell-based therapies to-date.

• Of the 17 new precision medicines 53% (N=9) are for cancer, 35% (N=6) for rare diseases, and 12% (N=2) for other disease treatments.

• 12 new in vitro diagnostic testing applications include three new blood-based biomarker tests to guide personalized oncology treatment decisions and several newly approved indications that will advance tumor-agnostic testing paradigms.

These new developments illustrate the importance of ensuring that our health systems are aligned with the latest science and technology so that we can deliver unprecedented benefits to both patients and health systems.

PMWC January 24-26, 2024 Silicon Valley, which will take place at the Santa Clara Convention Center, has designed the Emerging Therapeutics Track to cover critical aspects of new precision medicine developments. The focus will be on:

  • Gene & Cell Therapies for Rare Disease chaired by Yael Weiss (Mahzi Therapeutics) and Peter Marks (FDA)
  • Oncology Focused Gene Modified Cell Therapies chaired by Sharon Benzeno (Adaptive Biotechnologies),
  • Pharmacogenomics (PGx) chaired by Kelly Caudle (St. Jude Children’s Hospital)

 

These tracks will deep-dive into…

• why we must focus on the understanding of target/pathway biology to stop a disease in its track,

• why we must address underlying pathology drivers of a disease through a precision medicine approach, and

• why we need precision biomarkers to gain a deeper understanding of pharmacological response and possible drug-drug interactions, to decide on a treatment strategy, and to monitor drug response.

We are as excited as you to witness how recent progress in precision medicine and diagnostics continues to shape our approach to disease prevention and intervention and invite you all to join the next Precision Medicine World Conference, PMWC January 24-26, 2024, that brings stakeholders from across the industry together to engage in this important dialogue and influence the trajectory of modern health care.

Take advantage of the expiring early registration discount and secure your spot today.

Sincerely,

Tal Behar

President & Co-founder, PMWC

PMWC 2024 Silicon Valley – January 24-26, 2024

The Precision Medicine World Conference (PMWC)

We are thrilled to share some groundbreaking developments in the field of precision medicine with you. Two promising new drug candidates, Leqembi and Donanemab, have shown great potential in slowing the progression of Alzheimer’s disease, marking a significant step forward in tackling this challenging condition.

But this is just the beginning, and we must continue advancing the drug pipeline to develop the next class of drugs centered around the biology of aging to ultimately stop Alzheimer’s and related diseases in their tracks. The goal should be to address the various underlying pathologies of the disease through a precision medicine approach. Precision medicine not only benefits the patient but also the overall health systems. In addition, a precision approach to medicine is in the long run expected to help control the overall cost of health care.

A recently published PMC report showed that newly approved precision medicines in 2022 include 12 new entities and 5 newly approved gene and cell-based therapies bringing the total to 37 new molecular entities approved by the FDA’s CDER. Furthermore, 12 in vitro diagnostic testing applications that underpin precision medicine strategies were also approved or cleared for several new or expanded indications which help inform targeted treatment decisions to improve drug safety and efficacy. Some report highlights include:

• The 12 new entities represent ~34% of all newly approved therapeutic molecular entities, accounting now for at least a quarter of new drug approvals for each of the last eight years.

• The five new gene or cell-based therapies include treatments for beta thalassemia, hemophilia B, and cerebral adrenoleukodystrophy, resulting in a total of 13 FDA-approved gene or cell-based therapies to-date.

• Of the 17 new precision medicines 53% (N=9) are for cancer, 35% (N=6) for rare diseases, and 12% (N=2) for other disease treatments.

• 12 new in vitro diagnostic testing applications include three new blood-based biomarker tests to guide personalized oncology treatment decisions and several newly approved indications that will advance tumor-agnostic testing paradigms.

These new developments illustrate the importance of ensuring that our health systems are aligned with the latest science and technology so that we can deliver unprecedented benefits to both patients and health systems.

PMWC January 24-26, 2024 Silicon Valley, which will take place at the Santa Clara Convention Center, has designed the Emerging Therapeutics Track to cover critical aspects of new precision medicine developments. The focus will be on:

  • Gene & Cell Therapies for Rare Disease chaired by Yael Weiss (Mahzi Therapeutics) and Peter Marks (FDA)
  • Oncology Focused Gene Modified Cell Therapies chaired by Sharon Benzeno (Adaptive Biotechnologies),
  • Pharmacogenomics (PGx) chaired by Kelly Caudle (St. Jude Children’s Hospital)


These tracks will deep-dive into…

• why we must focus on the understanding of target/pathway biology to stop a disease in its track,

• why we must address underlying pathology drivers of a disease through a precision medicine approach, and

• why we need precision biomarkers to gain a deeper understanding of pharmacological response and possible drug-drug interactions, to decide on a treatment strategy, and to monitor drug response.

We are as excited as you to witness how recent progress in precision medicine and diagnostics continues to shape our approach to disease prevention and intervention and invite you all to join the next Precision Medicine World Conference, PMWC January 24-26, 2024, that brings stakeholders from across the industry together to engage in this important dialogue and influence the trajectory of modern health care.

Take advantage of the expiring early registration discount and secure your spot today.

Sincerely,

Tal Behar

President & Co-founder, PMWC

PMWC 2024 Silicon Valley – January 24-26, 2024

The Precision Medicine World Conference (PMWC)

#PMWC24

Follow PMWC on these social networks

#PMWC24 Follow PMWC on these social networks

PMWC Overview

Overview

PMWC, the “Precision Medicine World Conference” is the largest & original annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization & collaboration in an effort to accelerate the development and spread of precision medicine.


Since 2009, recognized as a vital cornerstone for all constituents of the health care and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.

Testimonials

Format

The conference format consists of five parallel talks spanning 3 full days. Main Tracks 1-4 include sessions by leaders in the commercial, pharmaceutical, academic, government, regulatory, venture capital, and non-profit arenas that deliver a broad and up-to-date array of content across the various facets of precision medicine. Session discussions focus on time-relevant aspects with a selected set of key stakeholders, while commercial sessions cover the latest developments in technologies that are instrumental for the success of further adoption of precision medicine.

Additional 2 Tracks, feature Showcases: companies and research institutions can promote their platforms, launch products, and share research developments to a targeted audience(Apply) & the Most Promising Company Competition: identifies “rising stars” startup companies in the area of diagnostics, therapeutics, and health tech via a platform that includes leading investors.

For over a decade, PMWC has recognized individuals who have played a significant role in transforming health care by advancing precision medicine in the clinic with the Luminary and Pioneer Awards. The honorees’ numerous technological and scientific contributions have expedited this transformation as demonstrated by the clinical adoption of precision medicine, and the ongoing introductions of novel clinical applications. For a deeper look into the fascinating achievements of our past awardees see the awards page.

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by FEB. 29TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required